Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Subjects With Hypertension

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Subjects With Hypertension

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Esaxerenone (Primary) ; Eplerenone
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Sponsors Daiichi Sankyo Inc

Most Recent Events

  • 12 May 2019 Primary endpoint (Change from baseline in sitting systolic and diastolic blood pressure (5mg)) has been met, according to the results published in the Journal of Human Hypertension
  • 12 May 2019 Primary endpoint (Change from baseline in sitting systolic and diastolic blood pressure (2.5mg)) has been met, according to the results published in the Journal of Human Hypertension
  • 12 May 2019 Results published in the Journal of Human Hypertension

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top